TransMedics Group Inc vs Vistra Corp — how do they compare? TransMedics Group Inc trades at $80.47 (market cap $2.74B), while Vistra Corp trades at $156.89 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 19.1× TransMedics Group Inc's market cap, and Vistra Corp pays a 0.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vistra Corp for 32 Days on average.
| TMDX | VST | |
|---|---|---|
Market Cap | $2.74B | $52.41B |
Volume | 949,331 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $150.42 | $210.85 |
52-Week Low | $61.99 | $134.71 |
Typical Hold Time | 24 Days | 32 Days |
Enterprise Value | $3.13B | $74.34B |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Vistra Corp (VST) trades at $156.19, down 6.32% today, but maintains strong analyst support with 91% buy ratings and a $215.23 consensus target. The stock shows bullish technical signals with support at $152 and resistance at $164, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Vistra presents compelling growth potential as a key beneficiary of AI infrastructure expansion, with strong profitability metrics and institutional backing. However, investors face risks from volatile earnings performance (two recent EPS misses) and execution challenges in capital-intensive energy projects. The stock's current discount to analyst targets offers upside potential if the company can consistently deliver on its nuclear expansion and data center power contracts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →